The purpose of value-based insurance is to design copays, coinsurance, deductibles and other benefit features that will encourage people to use services that have been demonstrated to be cost-effective, while discouraging use of services for which there is less certain evidence of beneficial effects. These designs have been around long enough now that researchers have examined their effects on both quality and costs. An article in Health Affairs reviews the results of these early studies. (Health Affairs Article) All of the studies focused on prescription drugs, which typically have elaborate copay designs. Thirteen studies were selected, all of which involved copayment reductions on drugs that treated chronic diseases. The studies were all considered to have good to excellent methodological quality. All of the studies showed an improvement in medication adherence after one year, by an average of 3%. Some showed continuing adherence gains beyond one year. The adherence response varied across drug types. Several of the studies examined a potential effect of copay reductions on medical and drug spending. As might be expected, drug spending rose. The effect on overall health spending was less clear, but appeared to be an insignificant change, up or down although some individual studies showed an increase and some a decrease. Two studies looked at utilization and found decreases in ER use, physician visits and hospitalizations. An important future goal of research should be to track overall spending and utilization changes in the long run.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
Mental health company Headway makes, well, headway, by raising an impressive $125 million round of new capital. The company connects patients with mental health providers and facilitates providers working with...
October 11, 2023
Two health care firms owned by private equity firms are merging in a transaction supposedly valued at $3 billion. HealthComp administers self-funded plans for employers and other groups and Virgin...
September 27, 2023
NextGen, an electronic medical records firm, is being put out of its public company misery, as a PE firm will pay $1.6 billion for the one-time high-flier.
September 7, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace